The general requirements and expectations for current good manufacturing practices cgmp and current good tissue practices cgtp. Citation when referring to this article, please cite as s. Most of the above facilities are located in the nhs or uk academia. Article details pharmaceutical technology volume 40, number 3 page 78. Ctf cell therapy facility dc dendritic cell dmf drug master file. Pda technical report 56 application of phaseappropriate quality system and cgmp to the development of therapeutic protein drug substance pda, 2012. Preliminary hyperflask studies ensured the appropriate growth and viability of therapeutic cells produced with this technology. It meets a previously unmet need for a thorough facilityfocused resource, cell therapy. Actionoriented solutions for establishing cgmp manufacture of cell and gene therapies as companies progress their development programs towards commercialization. The pct mountain view facility in california is a gmp compliant, 25,000squarefoot cell therapy manufacturing facility with approximately 12,500 square feet of manufacturing operations space and 12,000 square feet of office space ample capacity for projects in all stages of development. Facility and cell therapy unit ctu at kings college london. Advice read and follow the guidances use prepre and pre.
As with the car t cell manufacturing process, generation of the vector stocks must take place in good manufacturing practice gmp facilities. Cgmp compliant manufacturing commercial cell therapy. Gmp manufacturing is not required for phase 1, but they are still expected to control manufacturing there is more than one way to be gmp compliant no two gmp facilities will be exactly alike facility design is dictated by the products being manufactured gmp may improve the product, but mostly it. Design and operation of gmp cell therapy facilities pact w. The center for cell and gene therapy houses two good manufacturing practices gmp facilities for the preparation of cell and gene therapy products for use in phase iii clinical trials.
Cell therapy cgmp facilities and manufacturing adrian. The current approach to cell and tissuebased therapy development requires using good manufacturing production facilities through master. Facts about the current good manufacturing practices. We recognize that not all of the legislation is finalized, so we recommend. The largescale manufacturing centre that will be built and run by the cell therapy catapult has not been included in this analysis. Article 631 of regulation eu no 53620143 also empowers the commission to adopt and publish detailed guidelines on good manufacturing practice applicable to investigational medicinal products. Cell source, method of collection supporting acceptance criteria for. Multifunctional facilities manufacturing both cell and gene therapies comprise 27% 1795 m2. Cell therapy product proposal uc san diego school of. Manufacturing practices that follow a rigorous cgmp system, designed to produce materials that meet all finished. The initial risk analysis performed by developers identify the risks related to the product, its production and clinical use, and the evaluation covering the whole product development.
Not surprisingly, fda is not telling us to abandon. Schedule m guidelines pdf specified by the bureau of indian standards or local municipality, as the case may. Current good manufacturing practices cgmp in pharmaceutical. Oct 16, 2012 any procedure related to cbmps requires a strict control in c gmp facilities. Any procedure related to cbmps requires a strict control in c gmp facilities. The act speci cally mentions conformity with cgmp only in relation to medical drugs and devices. Title highquality cell therapy facility at the utrecht life. Dec 25, 2014 in cell therapy, the use of autologous and allogenic human mesenchymal stem cells is rising.
Quality cell therapy manufacturing by design nature. In addition there is a quality control laboratory, that performs testing on products and the manufacturing environment, and a flow cytometry facility for. Provide a list of references and attach pdf of prior publications. Based on this reveiw, the facility s design meets or exceeds guidelines for clinical research purposes.
A cgmp facility is a production facility for the manufacturing of pharmaceutical or cellular products. Practical considerations for manufacturing cell therapy. Cell therapy adrian gee editorcell therapy cgmp facilities and manufacturing123 editor adrian gee baylor colleg. This chapter is an attempt to elucidate what the minimum requirements for gmp facilities for gene and cell therapy products are and what is considered necessary to comply with the regulations in europe. Cell therapy cgmp facilities and manufacturing adrian gee. The suitability of a facility depends on the nature of the product not all state of the art facilities are ideal for every product gmp may improve the product, but mostly it allows you to control product quality and safety, and to help ensure manufacturing consistency gmp cannot prevent manufacturing. Quality control tests for living therapies are complex and often lengthy, requiring specialist knowledge by. Current us fda regulation of cell therapy andra miller, ph. Manufacturing and cgmp for cell and gene therapies. This shows that the uk has a strong manufacturing base to facilitate the translation of early phase academic research into the clinic. Please complete the sections below to request access to actl cgmp systems and facilities. Understanding good manufacturing practice and how biological industries can support cell therapy development in this editorial, learn more about what good manufacturing practice gmp means, how it could affect you and how biological industries can.
Eudralex the rules governing medicinal products in the. Fda outlines its operation for facility evaluation duane morris. Manufacturing and regulatory requirements for cell therapy products. Best practices for designing cellbased cgmp facilities. The center for cell and gene therapy houses two good manufacturing practices gmp.
Gmp cell therapy manufacturing facility cellular therapeutics. Cell therapy markets, trimark publications, july, 2007. Global cgmp manufacturing sites cell therapy manufacturing. Sep 14, 2017 fda outlines its operation for facility evaluation. What nobody tells you about cell therapy cgmp manufacturing william monteith, chief operating officer, hitachi chemical advanced therapeutics solutions january 5, 2018 pct services have helped many companies and research organizations develop their cell therapies from earlystage clinical trials into products ready for commercialization. Intercytex and cellular therapeutics are commercial organisations. Facilities should be designed and organ cell therapy. Manufacturing practice gmp facilities are required to produce cells used in these cell based treatments to ensure safety and meet quality standards. The uks mhra licensed gmp manufacturing facilities employ around 400 people fulltime, who are spread across dedicated cell therapy sites, 6 dedicated gene therapy sites and 4 multifunctional sites. Standardized car t cell manufacturing was established and validated before initiating hdcar1. Schmitt, phaseappropriate gmp, pharmaceutical technology 40. What nobody tells you about cell therapy cgmp manufacturing.
Transplantation of live cells as therapeutic agents is poised to offer new treatment options for a wide range of acute and chronic diseases. Accordingly, the supply of cells for clinical applications in highest quality is required. Early stage manufacturing considerations for cell therapy. Two positive pressure iso class 6 clean rooms with access to an additional suite to extend. Researchers in the center for cell and gene therapy at baylor college of medicine, texas childrens hospital and houston methodist hospital published new results in the medical journal science translational medicine. Quality control personnel partf cgmp sop templates and. Cell and gene therapy manufacturing processes require an underpinning pharmaceutical quality system and quality control qc laboratory, and all aspects of cell and gene therapy manufacturing require trained personnel. Manufacturing cell therapies national academy of medicine. Cell and gene therapy product development matrix cmc.
Guidance for industry food and drug administration. Current good manufacturing practices and the federal food. If these materials are to be exported to the eu, a qp visit is very helpful to enable release of the materials. Gmp facilities for manufacturing of advanced therapy medicinal products for clinical trials. The sterility of the vector is crucial because the. Cocoon technology, currently under development by lonza in collaboration with octane biotech, is based on an automated gmp inabox concept for autologous cell therapy manufacturing. Current good manufacturing practices cgmps if a product is not manufactured using good manufacturing practices, the fda can classify a product as adulterated even if it complies with all finished product specifications.
We maintain fda, usda, military and human grade manufacturing facilities. Rachel haddock, ms, is vice president of gmp operations, cell and gene therapy, at glaxosmithkline. The remainder of the gene therapy cleanroom space is distributed between uk academia and the nhs. A risk based approach can be used also to define the amount of scientific and clinical data for each cell therapy product. Brammers facilities are designed to be fully compliant for viral vector manufacturing under the fda code of federal regulations part 21 and the european advanced therapy medicinal products regulations. This new book presents the first balanced and highly practical view of guidelinestheir strengths, their limitations, and how they can be used most effectively to benefit health care. Facilities equipment needs briefly describe proposed plan of gmp manufacturing and characterization for the cell therapy product, including scaleformat of the process and duration of production campaign. Cellbased therapiesespecially stem cell therapies, regenerative medicine. The remainder of the gene therapy cleanroom space is distributed between uk academia and the nhs with 8 cleanrooms per site being the median.
The complex nature of cell therapy manufacturing requires welltrained, competent professionals. It includes the manufacturing space, the storage warehouse for raw. Design and operation of gmp cell therapy facilities pact w k hpact workshop april 10april 1011, 200711, 2007 doug padley mt ascpdoug padley mt ascp mayo clinic, rochester mn 332 hpc transplants in 2006 280 auto 52 allo mayo clinic human cellular therapy laboratory. Early stage cmc considerations for source materials and. Gmp facilities, academic research, government agencies, and. As hmscs are considered as an advanced therapy medicinal products atmp, they underlie the requirements of gmp and pat according to the authorities fda and ema. Mct minnesota molecular and cellular therapeutics facility mop manual of procedures msc mesenchymal stem cells nci national cancer institute. A third facility in new jersey designed to serve the needs of commercial stage cell and gene therapy development and manufacturing has recently launched.
Considering cell therapy product good manufacturing. Customize these sop templates and supporting documents to comply with cgmp requirements for quality control personnel. Guidelines for the clinical practice of medicine have been proposed as the solution to the whole range of current health care problems. The cgmp compliant cell therapy equipment can be installed in manageable grade d class 100,000 environment, providing biological and physical protection between the work and the user. The food and drug administration fda is amending the current good manufacturing practice cgmp regulations for human drugs, including biological products, to exempt most phase 1 investigational drugs from complying with the regulatory cgmp requirements. Clinicalgrade car t cells were produced in the gmp core facility of our institution from healthy donors, as well as from patients enrolled in the hdcar1 trial. Federal register current good manufacturing practice and. These novel drug candidates provide drastically improved patient outcomes and, in some cases, can be curative. In manufacturing pscts, it is often difficult development by design methodology. The field of cell and gene therapy is transforming the way patients, diagnosed with cancers or genetic diseases, can be treated.
The authors are participants in the activities of the forum on regenerative medicine of the national academies of sciences, engineering, and medicine. In these models, a central site is responsible for the production of the cell therapy product ctp, which is then delivered to the clini cal site for use. One aspect under investigation is the subtype of t cells used for car t cell therapy. Global cgmp manufacturing sites cell therapy services. Current good manufacturing practices cgmp in pharmaceutical industries current good manufacturing practice cgmp is to follow the current regulatory guidelines to produce the best quality pharmaceutical products with proper documentation and data integrity. Cellular therapy facility scottish centre for regenerative medicine 5. Our focus of expediting builds for gene and cell therapy manufacturing facilities provides your team with tremendous opportunity to quickly bring new products to the market. A technology roadmap to cell manufacturing technologies. Ccrm and the university health network uhn have partnered to design and build the centre for cell and vector production ccvp. Services and manufacturing baylor college of medicine. Pdf cgmpmanufactured human induced pluripotent stem cells. The plans for pact facility information, standard operating procedures sop, equipment and process validation, testing and results are described.
Cgmps, regulations enforced by fda, provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities. The general requirements and expectations for current good manufacturing practices cgmp and current good tissue practices cgtp, testing, and product standards are addressed. In our facility, we have successfully documented the utility of hyperstack units as an alternative to our existing cell factory process for manufacturing a cell therapy product before initiation of phase 3 manufacturing. Over 85% of the gene therapy capacity is commercially owned space.
Centralized manufacturing is attrac tive because it allows firms to achieve economies of scale and to ensure product consistency. Atmp, gene therapy, cell therapy, gmp, clinical grade, clean. Cellular therapeutics ltd has particular expertise in adoptive immune cell therapy for cancer, but the general field has wide application and the methodology and expertise of the company is more broadly. Manufacturing production license in the netherlands for the production of. A view into the challenges and contributions of gmp facilities. Any procedure related to cbmps requires a strict control in cgmp facilities. Schedule m is a part of drug and cosmetic act 1940. Department of medicine, karolinska institutet, karolinska university hospital huddinge, se14186 stockholm, sweden. Rayne cell therapy suite rcts and the wellcome trust brc clinical research.
Cell neil littman, kathy aschheim in a 20 roundtable co. Global cgmp manufacturing sites global facilities cell therapy products are unique they require specialized facilities, expert personnel, and dedicated resources to efficiently support clients development and manufacturing needs. Cell and gene therapy product development matrix cmc optimization research up to preind. The requirement that manufacturers comply with current good manufacturing practices originates in the federal food, drug and cosmetic act. Facilities should be designed and organcell therapy. Our specialized gmp facility is one of the eight facilities in nation that support adoptive t cell therapy based phase i and phase ii clinical trials that require gene modified tcells or bispecific antibody conjugated tcells. It includes the manufacturing space, the storage warehouse for raw and finished product and support laboratory areas. Evaluating contract manufacturing for biotech and cell.
98 1039 1222 478 1491 711 511 1406 64 1350 963 950 126 831 419 797 939 1416 1379 1642 1057 250 969 120 1102 134 107 13 1441 450 197 1117 696 1620 962 983 554 244 1134 763 1003 1216 44 186 5 22